2023年4月13日

共同Jeito資本,RA的資本管理和新生,融資輪也參與Bpifrance等從現有投資者通過其InnoBio 2基金,施羅德資本,BB Pureos Bioventures。Alentis療法打算使用資金的二期和一期項目領導臨床實驗的啤酒產品。F02和啤酒。C04, first-in-class anti-Claudin-1 (CLDN1)抗體,分別。啤酒。F02正在開發先進的治療腎、肺和肝纖維化同時啤酒。C04是一個潛在的治療目標CLDN1-positive腫瘤。一輪融資所得也將用於CLDN1的發展平台工程師CLDN1抗體藥物配合(ADC)和雙特異性抗體。沉默的效應函數,啤酒。F02設計針對硬ECM的纖維組織和器官。啤酒。C04效應函數,直接目標癌症而沉默CLDN1-mediated致癌信號。 It is designed to open up stiff extracellular matrix (ECM) in tumours with immune evasion mechanisms. Alentis Therapeutics CEO Dr Roberto Iacone said: “There are huge unmet needs in organ fibrosis and cancer, and this funding enables us to continue with the important work we’re doing in the CLDN1 space and generate clinical data from both our programmes. “We can now aggressively develop CLDN1 biology in oncology and continue with the recruitment of our organ fibrosis trials while advancing our ADC and bi-specific antibodies.” The latest financing round comes after the company received $67m in Series B funding in June 2021. Share this article